Retatrutide, a groundbreaking dual-acting glucose-dependent incretin agent, represents a significant progression in peptide treatments for the treatment of type 2 diabetes and, increasingly, obesity. Unlike many existing therapeutic interventions, retatrutide merges the actions of a GLP-1 receptor agonist and a GIP receptor activator, offering a mo